VRTXHealthcare · BiotechnologyThe 32 Wall Street analysts covering Vertex Pharmaceuticals, Inc. hold a median 12-month price target of $583 — +7.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 5 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Vertex Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on VRTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +7.4% from it.
Of the 20 most recent actions, 14 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Nov 2026 | Barclays | Maintains | Overweight | $617 → $626 |
| 3 Nov 2026 | Cantor Fitzgerald | Maintains | Overweight | $595 → $619 |
| 3 Nov 2026 | Goldman Sachs | Maintains | Buy | $654 → $725 |
| 3 Nov 2026 | JP Morgan | Maintains | Overweight | $560 → $570 |
| 3 Nov 2026 | Morgan Stanley | Maintains | Overweight | $665 → $660 |
| 3 Nov 2026 | RBC Capital | Maintains | Outperform | $576 → $600 |
| 3 Nov 2026 | Scotiabank | Maintains | Sector Outperform | $558 → $660 |
| 3 Nov 2026 | Stifel | Maintains | Hold | $500 → $563 |
| 3 Nov 2026 | TD Cowen | Maintains | Buy | $550 → $575 |
| 3 Nov 2026 | UBS | Maintains | Buy | $615 → $640 |
| 3 Nov 2026 | Wells Fargo | Maintains | Overweight | $550 → $650 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $570 → $576 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 28 Sept 2026 | UBS | Maintains | Buy | — |
| 28 Sept 2026 | UBS | Maintains | Buy | $585 → $615 |
| 11 Sept 2026 | JP Morgan | Reinstates | Overweight | $515 → $560 |
| 2 Sept 2026 | Morgan Stanley | Reinstates | Overweight | $665 |
| 5 Aug 2026 | Barclays | Maintains | Overweight | — |
| 5 Aug 2026 | Barclays | Maintains | Overweight | $615 → $617 |
| 5 Aug 2026 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VRTX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Nov 2026, Vertex Pharmaceuticals, Inc. returned +30.1% against +9.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 12% of US stocks
Cheaper than 14% of US stocks
Cheaper than 9% of US stocks
Higher than 57% of US stocks
Higher than 13% of US stocks
Higher than 94% of US stocks
Higher than 90% of US stocks
Higher than 89% of US stocks
Higher than 82% of US stocks
Higher than 93% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vertex Pharmaceuticals, Inc. has a market value of $137.5B and an enterprise value of $139.4B.
Revenue in the twelve months to 30 June 2026: $12.6B. The latest quarter grew 11.8% year on year.
Net income over the same four quarters: $4.4B, a 35.0% net margin.
Diluted earnings per share, trailing twelve months: $17.18.
Free cash flow in the twelve months to 30 June 2026: $3.8B.
Vertex Pharmaceuticals, Inc. spent $2.3B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 34.9×; forward P/E: 27.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Vertex Pharmaceuticals, Inc. employs 6,400 people — $2.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vertex Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The Motley Fool argues that Vertex's cystic fibrosis position remains highly durable and that its diversification efforts are gradually advancing, with further efforts ahead.
Why it matters — VRTX watchers may note the article's focus on the company's established cystic fibrosis business and its expanding diversification efforts.
Vertex announced that management representatives Susie Lisa and Manisha Pai will participate in fireside chats at three upcoming investor conferences. The excerpt gives details for their appearance at the UBS Global Biopharma Conference on November 16, 2026.
Why it matters — The conference appearances provide VRTX watchers with scheduled opportunities to hear from the company’s investor relations representatives.
Vertex Pharmaceuticals reported Q3 fiscal 2027 revenue of $3.44 billion, up 12% year over year, driven by cystic fibrosis and newer products CASGEVY and PALSONIFY.
Why it matters — The revenue growth and cited product contributions are relevant to VRTX watchers assessing the company’s sales performance.
Vertex beat Q3 revenue estimates and raised its 2026 outlook, with growth from CF therapies and newer drugs. Acquisition costs pressured earnings.
Why it matters — The update highlights revenue and outlook strength alongside acquisition-related pressure on earnings.
CRISPR Therapeutics reported third-quarter sales above expectations as Casgevy sales surged, alongside expanding pediatric approvals and progress across multiple clinical programs. Its quarterly loss was wider than expected.
Why it matters — The item concerns Casgevy, which is relevant to VRTX watchers because the excerpt identifies its sales as a driver of CRISPR Therapeutics’ results.
The 32 Wall Street analysts covering Vertex Pharmaceuticals, Inc. have a median 12-month price target of $583, with estimates ranging from $350 to $725. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 32 analysts covering Vertex Pharmaceuticals, Inc., 26 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Vertex Pharmaceuticals, Inc. 62 out of 100 across roughly 4,600 US stocks as at 5 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Nov 2026, Vertex Pharmaceuticals, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 32 analysts implies +7.4% from the last close, and Ticker Nerd's factor model ranks Vertex Pharmaceuticals, Inc. 62 out of 100 as at 5 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vertex Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $350 to $725 over the next 12 months.
Vertex Pharmaceuticals, Inc. returned +30.1% over the 12 months to 5 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Vertex Pharmaceuticals Incorporated Common Stock represents ownership in Vertex Pharmaceuticals Incorporated, a global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company’s current portfolio is centered on cystic fibrosis therapies and has expanded into additional specialty disease areas through products such as CASGEVY and JOURNAVX.
The most recent item we track (The Motley Fool, 5 Nov 2026): "Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years". The Motley Fool argues that Vertex's cystic fibrosis position remains highly durable and that its diversification efforts are gradually advancing, with further efforts ahead.
Vertex Pharmaceuticals Incorporated Common Stock represents ownership in Vertex Pharmaceuticals Incorporated, a global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company’s current portfolio is centered on cystic fibrosis therapies and has expanded into additional specialty disease areas through products such as CASGEVY and JOURNAVX. Vertex serves patients across the United States, Europe, and other international markets, with a business model that combines specialized research, regulatory development, manufacturing, and commercialization capabilities. The company is known for operating in highly scientific and tightly regulated therapeutic markets, where innovation, clinical expertise, and product execution are central to its role. Vertex Pharmaceuticals Incorporated Common Stock is used by investors to track and participate in the performance of a biotechnology business with a strong presence in specialty pharmaceuticals and advanced medicine development.
CEO Dr. Reshma Kewalramani FASN, M.D. · 6,400 employees · United States · https://www.vrtx.com
